在乳腺癌中V Leiden因子和V rs6028因子的功能和调节作用
Sara Marie Lind1,2, Marit Sletten1, Carola Elisabeth Henriksson2,3
1Department of Medical Genetics, Oslo University Hospital and University of Oslo, 0450 Oslo, Norway.
Genes
|July 29, 2025
概括
特定的F5基因变异,FV莱登 (rs6025) 和rs6028,增加凝血因子V (FV) 的表达和活性. 这些变体可能会增强FV.
科学领域:
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
背景情况:
- 癌症的进展与静血系统有关.
- 凝血因子V (FV) 在凝血中起作用,具有促凝和抗凝功能.
- FV基因表达 (F5) 和F5变异与乳腺癌进展有关,但它们的直接影响尚不清楚.
研究的目的:
- 研究F5变体,特别是FV莱登 (F5rs6025) 和F5rs6028,对乳腺癌细胞中的FV表达,凝固活性和亡的影响.
- 检查F5变异在F5基因表达中的F5变异的调节潜力.
主要方法:
- 用F5野生型,F5 rs6025或F5 rs6028的过度表达等离子体感染MDA-MB-231乳腺癌细胞.
- 在体外分析F5mRNA,FV蛋白水平,FV凝固剂活性和亡.
- 在体内表达量化特征位点 (eQTL) 分析以评估调控效应并确定转录因子结合位点.
主要成果:
- 与空载体相比,野生型F5的过度表达增加了F5mRNA,FV蛋白和亡.
- 与野生类型F5.5相比,F5 rs6025和F5 rs6028变体进一步提高了F5mRNA,FV蛋白,凝固剂活性和亡.
- 在分析表明F5 rs6028的调节作用,并确定了F5 rs6025附近的潜在转录因子结合位.
结论:
- F5 rs6025和F5 rs6028变体显示了对FV合成的调节作用.
- 这些F5变异可能会影响乳腺癌细胞的亡.
- 研究的F5变种可能会增强乳腺癌中FV的瘤抑制功能.
相关概念视频
Rous Sarcoma Virus (RSV) and Cancer
5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.4K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Factors Affecting Protein-Drug Binding: Protein-Related Factors
260
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
260
Factors Affecting Protein-Drug Binding: Patient-Related Factors
114
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
114
Factors Affecting Protein-Drug Binding: Drug-Related Factors
198
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
198


